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Abstract
Summary Active case finding for osteoporosis is used to
identify patients at high fracture risk who may benefit from
preventive drug treatment. We investigated the relative
weight that women place on various aspects of preventive
drugs in a discrete choice experiment. Our patients said
they were prepared to take preventive drugs even if side
effects were expected.
Introduction Active case finding for osteoporosis is used to
identify patients who may benefit from preventive drugs. We
aimed to elicit the relative weight that patients place on
various aspects of preventive drug treatment for osteoporosis.
Methods We designed a discrete choice experiment, in
which women had to choose between drug profiles that
differed in five treatment attributes: effectiveness, side
effects (nausea), total treatment duration, route of drug
administration, and out-of-pocket costs. We included 120
women aged 60 years and older, identified by osteoporosis
case finding in 34 general practices in the Netherlands. A
conditional logit regression model was used to analyse the
relative importance of treatment attributes, the trade-offs
that women were willing to make between attributes, and
their willingness to pay.
Results All treatment attributes proved to be important for
women’s choices. A reduction of the relative 10-year risk of
hip fracture by 40% or more by the drug was considered to
compensate for nausea as a side effect. Women were
prepared to pay an out-of-pocket contribution for the
currently available drug treatment (bisphosphonate) if the
fracture risk reduction was at least 12%.
Conclusions Women identified by active osteoporosis case
finding stated to be prepared to take preventive drugs, even
if side effects were expected and some out-of-pocket
contribution was required.
Keywords Discretechoiceexperiment.Drugtreatment.
Osteoporosis.Preferences.Prevention
Introduction
Osteoporosis constitutes a major public health problem. In
the USA, approximately 1.5 million fractures annually are
attributable to osteoporosis, including 700,000 vertebral
fractures, 250,000 distal forearm (Colles’) fractures,
250,000 hip fractures, and 300,000 fractures of other limb
sites [1]. Osteoporotic fractures have a major economic
impact on society and on the quality of life of patients [2,
3]. Preventive drug treatments, such as bisphosphonates
(alendronate, etidronate, and risedronate) reduce the risk of
osteoporotic fractures in women with postmenopausal
osteoporosis by stabilising or increasing the bone density
[4–8]. Various practice guidelines recommend a case-
finding approach to identify persons with a high risk of
osteoporotic fractures [9, 10]. Once identified, women are
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insight into the relative importance of attributes of
preventive drug treatment (such as a bisphosphonate) is
limited. Ideally, patients with high fracture risks make an
informed decision on taking preventive medication, based
on deliberative trade-offs between the burden of medication
(e.g., duration, side effects), individual fracture risk, and
treatment efficacy.
This study investigated patients’ preferences for preven-
tive drug treatment for osteoporosis by means of a discrete
choice experiment (DCE), where attributes of hypothetical
drug treatments were systematically varied. DCEs have
increasingly been used in health care as an approach to
elicit patient preferences [11–15]. The DCE was used to
determine the trade-offs that community-dwelling elderly
women make between the different treatment attributes, and
their willingness to pay for each attribute. We also
investigated whether high-risk patients (i.e., 10-year risk
of a hip fracture greater than 6%) had different preferences
than low-risk patients.
Materials and methods
Study sample and elicitation mode
We recruited community-dwelling elderly women (aged
over 60 years) from 34 general practices (in the area of
Rotterdam, the Netherlands), who participated in a study on
osteoporosis case finding. This latter study used a simple
risk score to identify women at high risk of osteoporotic
fractures, based on Dutch guidelines [9, 10]. After
completion of the risk score, women were asked if they
were willing to participate in the current study. Women
were informed about their lifetime fracture risk (low or
high). We aimed to administer the DCE questionnaire to
120 women with an overrepresentation of women with a
high fracture risk (n=60). Earlier studies have shown that
this number of respondents is sufficiently large for reliable
statistical analyses [15–19].
The DCE questionnaire was sent by post and a trained
medical student collected the answers from the respondent
by telephone a week later.
DCE
DCEsassumethatagivenhealthcareinterventionortreatment
can be described by its characteristics (attributes) and that any
woman’s preferences for an intervention or treatment are
determined by the levels of the attributes [15]. Attributes
should be identified beforehand as potentially important for
the choice of an intervention or treatment [20]. The relative
importance of attributes and the trade-offs that women make
between them can be assessed when women are offered a
series of choices between treatment alternatives that have
different combinations of attribute levels [21].
Attributes and attribute levels
The choiceofattributesandthe attribute levelswas basedona
literature review focusing on bisphosphonates, expert inter-
views (n=5; three GPs, the director of the Dutch Osteopo-
rosis Foundation, and a specialist in internal medicine), and
personal interviews with 15 community-dwelling women
aged over 60 years (i.e., the target group) with and without
osteoporosis (n=10 and n=5, respectively). We asked
experts and women in the interviews to comment on and
complete the list of treatment attributes that was created from
literature review. We also asked women to rank the attributes
from most important to less important with respect to their
preferences for osteoporosis treatment. The number of
attributes in a DCE is limited (due to impact on the random
component variability) [22], and the ranking results allowed
us to make an a priori selection of the most relevant
attributes. These were: effectiveness of treatment, side effect
of treatment (nausea), total treatment duration, route of drug
administration, and costs (Table 1). Most of the attribute
levels of preventive drug treatment for osteoporosis in our
experiment were directly related to bisphosphonates. We also
included some hypothetical levels. By including hypothetical
levels we can extend the assessment of preferences beyond
the currently available treatments for osteoporosis to treat-
ments that are not yet traded in real markets, but may
become available in the future. The results are potentially
useful to guide the development of new drugs for osteopo-
rosis, because we identified what is important for such a drug
to be accepted by the target group. The interviews helped us
to determine the hypothetical attribute levels. For example,
we determined the levels for the cost-attribute by asking
women directly their willingness to pay for preventive drug
treatment for osteoporosis.
Study design and questionnaire
The combination of attributes and attribute levels (four
attributes with four levels, and one attribute with two levels)
resulted in 512 hypothetical drug treatment profiles (4
4 *2
1).
For obvious practical reasons, not all of these could be used
in a questionnaire. Therefore, we generated a sample of
hypothetical drug treatment profiles from all these 512 drug
profiles for the questionnaire (i.e., we used a fractional
factorial design) [23]. This sample must be large enough to
estimate at least all main effects in a regression analysis. In
our case, a sample of 16 hypothetical drug treatment profiles
was sufficient [22]. Based on these 16 drug treatment
profiles, choice sets were created. Each choice set consisted
1030 Osteoporos Int (2008) 19:1029–1037of two drug treatment profiles and a ‘no drug’ treatment
option; see Fig. 1 for an example. The first drug treatment
profile (i.e., Treatment A) of each choice set was always one
of the 16 hypothetical drug treatment profiles selected for the
fractional factorial design. We created the second drug
treatment profile (i.e., Treatment B) of each choice set by
means of a specific technique (‘foldover’)t oe n s u r em i n i m a l
overlap of attribute levels (i.e., Treatment A and Treatment B
always had different attribute levels in each choice set). Too
much overlap would reduce the information obtained on
trade-offs between attribute levels. Our questionnaire
contained 16 choice sets (see Appendix 1). We included a
dominant choice set in the questionnaire to test for rationality
(i.e., a choice set including one drug treatment profile
characterized by logically preferable levels on all attributes).
The questionnaire started with a detailed written description
of each attribute and its levels (the complete questionnaire is
available from the authors on request). The questionnaire
was pilot tested (n=10) to check for any problems in
interpretation and face validity.
Analyses
The DCE was analysed by taking each choice among the
three options (two drug treatment profiles, and a ‘no drug’
treatment option) as an observation. Data from respondents
who failed the dominant question were excluded from
further analyses. The remaining observations were analysed
by a conditional logit regression model. Assuming that all
attributes have an independent influence on a woman’s
preference, the following model was estimated [22]:
V ¼ β0 þ β1TABLETweekly þ β2INJECTIONfourmonths
þ β3INJECTIONmonthly þ β4EFFECTIVENESS
þ β5NAUSEA þ β6TIME þ β7COST
where
– V represents the utility derived for preventive osteopo-
rosis drug treatment.
– β0 is a constant reflecting the respondents’ preference
for receiving osteoporosis drug treatment relative to no
osteoporosis drug treatment.
Table 1 Attributes and levels for osteoporosis drug treatment
Attributes and levels Beta coefficients in
regression analysis
Route of drug administration:
Tablet once a month (TABLETmonthly)
Tablet once a week (TABLETweekly) β1
Injection by GP every four months
(INJECTIONfourmonths)
β2
Injection by GP every month
(INJECTIONmonthly)
β3
10–year risk redution of a hip fracture (%)
(EFFECTIVENESS):
β4
5
10
25
50
Nausea (for up to two hours after intake)
(NAUSEA):
β5
No (0)
Yes (1)
Total treatment duration (years) (TIME) β6
1
2
5
10
Total cost to you (€) (COST) β7
0
120
240
720
Please, compare ‘Treatment A’ with ‘Treatment B’, and ‘No treatment’. Which preventive
treatment for osteoporosis do you prefer? 
 
Treatment A  Treatment B  No treatment 
Route of drug 
administration 
Tablet 
once a week 
Injection by GP 
every 4 months  Not applicable 
10-year risk reduction of 
a hip fracture  10% 0% 
Nausea (during two 
hours after use)  Yes No 
Total treatment duration  2 years  5 years  0 years 
Total cost to you  
(thus per month) 
0 
(   0) 
   120 
(   2) 
   0 
(   0) 
 
Which treatment     0  Treatment A        0 Treatment B        0 No treatment 
do you prefer? 
25%
No
Fig. 1 Example of a choice set
as presented in the questionnaire
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importance of each attribute (Table 1). β1 to β3 are
dummy variables of the attribute ‘route of drug admin-
istration’, with tablet once a month as the base level.
The absolute value of V has no direct interpretation [22].
The sign of a coefficient reflects whether the attribute has a
positive or negative effect on utility. The value of a
coefficient indicates the relative importance of the
corresponding attribute. A statistically significant coefficient
was interpreted as indicating that the respondent considered
the attribute important. A priori we expected all attributes to
be important, and that only the attribute ‘effectiveness’
would have a positive effect. The utility from the ‘no drug’
treatment option was normalized to zero. The trade-offs that
the respondents were willing to make between the attributes
were estimated by the ratios of the coefficients. For example,
β5/β6 represents an estimate of how much longer the
respondent is willing to take osteoporosis drug treatment
(in years) to avoid nausea. The value of coefficient β7 is
used to estimate the willingness to pay (WTP). For example,
the WTP to avoid nausea was estimated as β5/−β7,w h e r eβ7
represents the importance of a 100 euro change in price.
We conducted a subgroup analysis by using interaction
terms in the conditional logit regression model to assess
whether high-risk patients (i.e., 10-year risk of a hip
fracture higher than 6%) had different preferences than
low-risk patients.
Results
Respondents
Of the 181 women (76 low and 105 high fracture risk
patients) invited, 120 responded (overall response rate 120/
181=66%; 60/76 (79%) and 60/105 (57%) for low and high
fracture risk patients, respectively). Low and high fracture
risk patients did not differ in educational level (χ
2 test, p=
0.22), but the high fracture risk patients were older, and
more frequently lived without a partner (Table 2).
DCE results
Most women indicated that they found the DCE questions
(very) clear and had no difficulty in completing the question-
naire. In total, 117 of 120 women (98%) passed the dominant
question. All coefficients were significant (Table 3). All signs
were consistent with a priori expectations. The positive
constant term suggests that respondents preferred drug
treatment over ‘no drug’ treatment if all other attributes were
set to zero. The positive sign of the coefficient ‘effectiveness’
indicates that women preferred a drug treatment with a
higher risk reduction of 10-year risk of a hip fracture over a
drug treatment with a lower risk reduction. The negative
signs for the other coefficients indicate that women preferred
a cheaper and shorter drug treatment without nausea. A
monthly tablet was preferred to other routes of drug
administration (i.e., weekly tablet or injection).
The magnitude of the attribute coefficients corresponds
with the relative importance of the attributes. For a correct
interpretation of the comparison of the coefficients of the
attributes, we need to pay attention to the different units of
measurement. For example, the coefficient of 0.28 of
‘effectiveness’ implies the increase in utility per 10% of risk
reduction. A risk reduction of 40% is four times larger than
10% risk reduction. Thus, a risk reduction of 40% implies a
utility of 1.10 for the attribute ‘effectiveness’ (i.e., four
multiplied with the coefficient of 0.28 of ‘effectiveness’). A
superficial comparison of the coefficients in Table 3 may
Table 2 Respondent
characteristics
aSignificant difference be-
tween low and high fracture
risk patient groups
*Significant at the 5% level
All patients (%) Low fracture risk
patients (%)
High fracture risk
patients (%)
P value
a
Group 120 (100) 60 (50.0) 60 (50.0)
Age (years) <0.001*
60–64 28 (23.3) 21 (35.0) 7 (11.7)
64–69 18 (15.0) 11 (18.3) 7 (11.7)
70–74 20 (16.7) 17 (28.3) 3 (5.0)
75–79 28 (23.3) 10 (16.7) 28 (30.0)
80 and older 26 (21.1) 1 (1.7) 25 (41.7)
Household <0.001*
Single 53 (44.2) 17 (28.3) 36 (60.0)
With partner 67 (55.8) 43 (71.7) 24 (40.0)
Educational level 0.215
Low 63 (52.5) 31 (51.7) 32 (53.3)
Intermediate 46 (38.3) 26 (43.3) 20 (33.3)
High 11 (9.2) 3 (5.0) 8 (13.3)
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effect had a larger influence on women’s choices for
preventive drug treatment than the attribute ‘effectiveness’.
As shown in the computation above, a risk reduction of more
than 40% contributes more to the utility of a preventive drug
treatment for osteoporosis than absence of nausea. A 40%
risk reduction (i.e., utility 1.10) compensates for the disutility
of minus 1.10 of the attribute ‘nausea’.
A positive utility value of a specific drug profile
indicates a preference for that treatment to no treatment.
The utility of a currently most frequently used preventive
osteoporosis drug treatment (bisphosphonate taken as a
weekly tablet, approximately 30% fracture risk reduction,
nausea as a possible side effect, total treatment duration of
five years, and no out-of-pocket payment) equals
V ¼ 1:23   0:31 TABLETweekly ðÞ þ 3:0
  0:28 EFFECTIVENESS ðÞ   1:10 NAUSEA ðÞ   5
  0:04 TIME ðÞ   0   0:15 COST ðÞ ¼ 0:46:
This outcome has a positive sign. Thus, the women in
our sample preferred this drug treatment over no treatment.
Trade-offs
Based on the expressed preferences, women were prepared
to adhere to drug treatment an estimated 5.7 years longer to
change from an injection every 4 months to a tablet once a
month, if all other attributes remained constant (Table 4).
For every 10% additional fracture risk reduction, they were
prepared to adhere to drug treatment 7.5 years longer.
Respondents were willing to pay an extra total amount of
752 to avoid nausea as a side effect, or 26 for every 1-year
decrease in total drug treatment duration.
For bisphosphonates, we estimated that respondents
were willing to pay up to an estimated 338 euro out-of-
pocket payment to receive treatment compared with no
treatment (WTP=847 (constant)−212 (weekly tablet) +
3.0*195 (risk reduction) – 752 (side effect nausea) – 5*26
(treatment duration)). They would thus be willing to pay for
this treatment if the fracture risk reduction was at least 12 %
(see Appendix 2).
Table 4 Women’s time and monetary trade–offs for preventive osteoporosis drug treatment
Attribute Willingness to adhere
to the drug treatment
longer (years)
WTP for total
treatment (€)
Interpretation note
Constant (no drug treatment) 32.7 847 For drug treatment vs. no drug treatment
Drug administration (base level tablet once a month):
Tablet once a week 8.2 212 For change from tablet once a week to tablet once a month
Injection every 4 months 5.7 147 For change from injection every 4 months to tablet once a month
Injection once a month 11.7 304 For change from injection once a month to tablet once a month
Effectiveness 7.5 195 For 10% reduction in 10–year risk of a hip fracture
Side effect nausea 29.0 752 For change from side effect to no side effect
Treatment duration 26 For 1–year decrease in total drug treatment duration
Cost 3.9 For 100 euro decrease in drug treatment cost
WTP = willingness to pay
Table 3 Women’s preferences
for preventive osteoporosis
drug treatment
*Significant at the 5% level
Number of observations 5,589
(117 respondents×16 choices×
3 options per choice, minus 27
missing values), pseudo
R
2 =0.1847, log pseudo-
likelihood=−1668.7
Attribute Beta coefficient P value 95% CI
Constant (drug treatment) 1.23 <0.001* 0.81 1.66
Drug administration (basel level tablet once a month):
Table once a week −0.31 <0.001* −0.45 −0.17
Injection every four months −0.21 0.027* −0.41 −0.02
Injection once a month −0.44 <0.001* −0.64 −0.25
Effectiveness (10% risk reduction) 0.28 <0.001* 0.23 0.34
Side effect nausea −1.10 <0.001* −1.30 −0.89
Treatment duration (1 year) −0.04 <0.001* −0.06 −0.02
Cost (100) −0.15 <0.001* −0.18 −0.11
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The results of conditional logit regression modelling of data
from both risk groups are presented in Table 5. Only the
interaction between the effectiveness of treatment and risk
group was significant (p=0.05). Lower levels of effective-
ness of the preventive drug treatment for osteoporosis were
more acceptable to high-risk patients than to low-risk
patients. High-risk patients therefore accepted a less
effective drug to reduce their fracture risk.
Discussion
Women identified by active case finding for osteoporosis
said in this DCE that they were prepared to adhere to
preventive drug treatment. Treatment effectiveness (hip
fracture risk reduction), side effects (nausea), total
treatment duration, route of drug administration, and
out-of-pocket costs were all relevant to women’s prefer-
ences for drug treatment. Nausea as a side effect had a
large influence on women’s choices, though a risk
reduction of 40% or more was sufficient to make nausea
as a side effect acceptable. Patients with high fracture
risk were more prepared to take a less effective drug
treatment than low fracture risk patients.
This study illustrated the feasibility of DCE to elicit
elderly women’s preferences for osteoporosis drug treat-
ment. An acceptable fraction of potential respondents
agreed to participate in the experiment, and only 3 of 120
failed the dominant question. This study therefore adds to
the available literature on the usefulness of DCE to
investigate preferences for drug treatment [15, 24–26].
In a previous DCE investigating women’s preferences
for osteoporosis treatment, early postmenopausal women
were willing to use a tablet once a week if the drug
reduced the absolute lifetime risk of fracture by at least
10% [27]. In our study, we considered relative reductions
in 10-year risk of a hip fracture, which limits the
comparability between these two DCEs. According to
Fraenkel et al., women willing to consider a drug treatment
strongly preferred taking a tablet once a week rather than
having an injection in a doctor’s office. We also found that
women preferred a tablet once a week to injection once a
month, but that an injection in a doctor’s office every
4 months was preferred to having to take a tablet once a
week. This was in line with findings of another study which
showed that many women preferred annual injections to
weekly oral medication [28].
The women in our study showed a very positive
attitude towards preventive drug treatment for osteoporosis,
a n ds a i dt h e yw e r ep r e p a r e dt ot a k ep r e v e n t i v ed r u g
treatment even when the effectiveness of the treatment was
zero. This may reflect a kind of placebo effect for drug
treatment. In practice, a substantial proportion of women
discontinue treatment with bisphosphonates [29, 30].
Various patient characteristics (e.g., being retired) were
associated with a high compliance with treatment for
osteoporosis [31] .F u r t h e rr e s e a r c hi sn e e d e dt oi n v e s t i g a t e
why patients, who are prepared to start with bisphosphonates,
discontinue treatment.
The effectiveness of the preventive osteoporosis drug
treatment was less important for high-risk patients than for
low-risk patients. All patients had knowledge of lifetime
fracture risk (low or high). Patients at high risk were
probably more aware of the consequences of their fracture
risk than low-risk patients, and were therefore more
prepared to take a less effective drug treatment.
In our study we used a postal questionnaire and the
answers of the respondent were collected later by tele-
phone. The use of an interviewer can be regarded as a
strength in the design, because this procedure led to data
completeness as well as a check of a respondent’s
understanding. However, this design also had some
limitations. First, although we included nausea as the most
relevant gastrointestinal side effect, other gastrointestinal side
effects that are also common (e.g., stomach pain, heartburn)
Table 5 Differences between
low and high–risk patients’
preferences for preventive
osteoporosis drug treatment
*Significant at the 5% level
Number of observations 5,589
(117 patients (i.e., 58 low-risk
+59 high-risk patients)×16
choices×3 options per choice,
minus 27 missing values),
pseudo R
2 =0.1895, log pseu-
do-likelihood=−1658.8
Attribute Beta coefficient of low
risk patients
Beta coefficient of high
risk patients
P value
Constant (drug treatment) 1.178 1.316 0.748
Drug administration (basel level tablet once a month):
Table once a week −0.360 −0.255 0.464
Injection every 4 months −0.125 −0.317 0.323
Injection once a month −0.445 −0.454 0.966
Effectiveness (1% risk reduction) 0.023 0.034 0.050*
Side effect nausea −1.046 −1.161 0.582
Treatment duration (1 year) −0.033 −0.045 0.583
Cost (1 euro) −0.002 −0.001 0.435
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the most relevant attributes in our DCE using interviews, but
this careful procedure does not guarantee that attributes that
we did not include are irrelevant to women’s preferences for
osteoporosis treatment. Second, we studied main effects only,
since these generally account for 70% to 90% of explained
variance in a DCE [22]; specific combinations of attribute
levels may have specific effects that remained unidentified.
Third, the current results could be validated by comparison
with actual behaviour of women in drug treatment for
osteoporosis. Fourth, the respondents were women selected
by active case finding, which precludes generalization of the
findings to all women. On the other hand, women identified
by active osteoporosis case finding are those who will have
to decide about treatment and therefore constitute the most
relevant study group.
Patient-centered and demand-led care is becomingly
increasingly important in current medical practice. Under-
standing which and how drug treatment attributes influ-
ence women’s preferences for osteoporosis drug treatment
is important to optimize the treatment design that patients
will follow. The present study showed that the target
group may well accept the currently available bisphosph-
onates with sufficient margin (satisfactory effectiveness,
side effects, and so on); this is an important result for
policy decision-making on the introduction of active case
finding on a large scale, in addition to considerations
related to cost-effectiveness.
In conclusion, this DCE showed that women identified
by active osteoporosis case finding showed a positive
attitude to preventive drug treatment, even if side effects
(such as nausea) were expected and some out-of-pocket
contribution was required.
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Appendix
Appendix 1
Overview of the 16 choice sets used in our questionnaire.
I II III IV V I II IIIIV V
baadb cbbac  
dabcd abada
acbdc bdaad
ccaca ddbdb
abbcb bcadc
adabd babca
cabbc dbacd
dcabb adbcc
bdacc cabdd
dbaac acbbd
aaaaa bbbbb
bcbad cdaba
bbbba ccacb
ddbda aaaab
cdbab daabc
cbadd dcbaa
15
16
11
12
13
14
7
8
9
10
Choice set
1
2
3
4
Treatment A Treatment B
Attributes Attributes
5
6
Code book:
I
a
b
c
d
II
a
b
c
d
III
a
b
IV
a
b
c
d
V
a
b
c
d
Route of drug administration
Effectiveness
Side effects (nausea)
Total treatment duration
Out-of-pocket costs
1 year
2 years
5 years
10 years
no nausea
0
120
nausea for up to two hours after intake
5% risk reduction of a hip fracture
10% risk reduction of a hip fracture
25% risk reduction of a hip fracture
50% risk reduction of a hip fracture
tablet once a month
240
720
tablet once a week 
injection by GP every 4 months
injection by GP every month
Osteoporos Int (2008) 19:1029–1037 1035Treatment A of choice set 1 (i.e., code ‘baadb’)
represents a hypothetical preventive drug treatment for
osteoporosis with the following characteristics: tablet once
a week as a route of drug administration, 5% risk reduction
of a hip fracture as treatment effectiveness, no side effects
(nausea), total treatment duration of 10 years, and 120 euro
out-of-pocket costs for the entire treatment. In the ques-
tionnaire this treatment was presented with Treatment B of
choice set 1 (i.e., code ‘cbbac’) with the following
characteristics: injection by GP every 4 months as a route
of drug administration, 10% risk reduction of a hip fracture
as treatment effectiveness, nausea for up to two hours after
intake as a side effect, total treatment duration of 1 year,
and 240 euro out-of-pocket costs for the entire treatment.
Respondents had to choose between this Treatment A,
Treatment B, or no treatment.
Appendix 2
Regression line showing the relationship between risk
reduction (%) by means of bisphosphonate (tablet once a
week, side effect nausea, and treatment duration five years)
and WTP (€)
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